Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
134.62
-6.25 (-4.44%)
Streaming Delayed Price
Updated: 11:06 AM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
June 07, 2024
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
June 07, 2024
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.
Via
Benzinga
Topics
ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
June 07, 2024
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits
Via
Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
June 06, 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Novo Nordisk's Options Frenzy: What You Need to Know
June 06, 2024
Via
Benzinga
$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
June 03, 2024
Via
Benzinga
Why Quality Investors Should Delve into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for Investment Opportunities.
June 06, 2024
Why Quality-Oriented Investors Should Consider NYSE:NVO.
Via
Chartmill
Is Viking Therapeutics Stock a Buy on the Dip?
June 06, 2024
Short-term thinking is creating an intriguing opportunity for investors.
Via
The Motley Fool
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
June 06, 2024
The market for treating chronic kidney disease is nearly within reach.
Via
The Motley Fool
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
June 05, 2024
Via
Benzinga
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
June 05, 2024
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off.
Via
InvestorPlace
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
June 05, 2024
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment.
Via
Benzinga
Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock
June 04, 2024
There's new evidence suggesting the drug will find another large market.
Via
The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
June 03, 2024
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments
Via
MarketBeat
The Week Ahead: What's Next
June 02, 2024
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.
Via
Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
June 02, 2024
These two drugmakers have a lot more in common than their market-beating potential.
Via
The Motley Fool
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
June 02, 2024
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
Via
The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
June 01, 2024
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs.
Via
The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
June 01, 2024
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Novo Nordisk Is At The Vanguard Of The Weight Drug Revolution
May 31, 2024
Novo Nordisk is based in Denmark and sells around the world. Its largest market is the U.S., at about 50% of sales.
Via
Talk Markets
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
May 31, 2024
Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure or falsely labeled semaglutide products.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
May 31, 2024
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider.
Via
InvestorPlace
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
May 30, 2024
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks.
Via
Benzinga
Topics
ETFs
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
May 30, 2024
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030.
Via
Benzinga
Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting'
May 29, 2024
On CNBC's "Mad Money Lightning Round," Jim Cramer said Apple Inc. is a "buy" after iPhone sales in China saw a 52% year-on-year increase.
Via
Benzinga
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
May 29, 2024
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to...
Via
Benzinga
A New Name in Weight Loss Drugs
May 28, 2024
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.
Via
The Motley Fool
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
May 28, 2024
Novo Nordisk retains around 60% of the list price for its diabetes and obesity medications, Ozempic and Wegovy, after rebates and fees.
Via
Benzinga
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
May 28, 2024
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them.
Via
InvestorPlace
Topics
ETFs
Ozempic Maker Novo Nordisk's Increasing Influence On Denmark's Employment Raises Economic Concerns
May 28, 2024
The updated employment figures have heightened concerns about Denmark's economy becoming excessively dependent on Novo.
Via
Benzinga
Topics
Economy
Exposures
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.